Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
N Engl J Med
    November 2021
  1. SACHS RE, Bagley N
    Medicare Coverage of Aducanumab - Implications for State Budgets.
    N Engl J Med. 2021;385:2019-2021.
    >> Share

  2. ROBINSON JC
    Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    N Engl J Med. 2021;385:2017-2019.
    >> Share

    August 2021
  3. ALEXANDER GC, Knopman DS, Emerson SS, Ovbiagele B, et al
    Revisiting FDA Approval of Aducanumab.
    N Engl J Med. 2021;385:769-771.
    >> Share

  4. MINTUN MA, Wessels AM, Sims JR
    Donanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2021;385:667.
    >> Share

  5. ESPAY AJ
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021;385:666-667.
    >> Share

    July 2021
  6. RABINOVICI GD
    Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMp2111320.
    >> Share

  7. DUNN B, Stein P, Temple R, Cavazzoni P, et al
    An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMc2111960.
    >> Share

    May 2021
  8. LEVEY AI
    Progress with Treatments for Alzheimer's Disease.
    N Engl J Med. 2021;384:1762-1763.
    >> Share

    March 2021
  9. MINTUN MA, Lo AC, Duggan Evans C, Wessels AM, et al
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021 Mar 13. doi: 10.1056/NEJMoa2100708.
    >> Share

    October 2020
  10. FRIED LP, Rowe JW
    Health in Aging - Past, Present, and Future.
    N Engl J Med. 2020;383:1293-1296.
    >> Share

    June 2020
  11. INGELFINGER JR
    Kinder, Gentler Dementia-Friendly Alzheimer's Care.
    N Engl J Med. 2020;382:2487-2489.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016